Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Tóm tắt
The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung adenocarcinoma are poorly characterized. We performed an integrative analysis of genomic, transcriptomic, and proteomic data from early-stage and chemorefractory lung adenocarcinoma and identified three robust subsets of KRAS-mutant lung adenocarcinoma dominated, respectively, by co-occurring genetic events in STK11/LKB1 (the KL subgroup), TP53 (KP), and CDKN2A/B inactivation coupled with low expression of the NKX2-1 (TTF1) transcription factor (KC). We further revealed biologically and therapeutically relevant differences between the subgroups. KC tumors frequently exhibited mucinous histology and suppressed mTORC1 signaling. KL tumors had high rates of KEAP1 mutational inactivation and expressed lower levels of immune markers, including PD-L1. KP tumors demonstrated higher levels of somatic mutations, inflammatory markers, immune checkpoint effector molecules, and improved relapse-free survival. Differences in drug sensitivity patterns were also observed; notably, KL cells showed increased vulnerability to HSP90-inhibitor therapy. This work provides evidence that co-occurring genomic alterations identify subgroups of KRAS-mutant lung adenocarcinoma with distinct biology and therapeutic vulnerabilities.
Significance: Co-occurring genetic alterations in STK11/LKB1, TP53, and CDKN2A/B—the latter coupled with low TTF1 expression—define three major subgroups of KRAS-mutant lung adenocarcinoma with distinct biology, patterns of immune-system engagement, and therapeutic vulnerabilities. Cancer Discov; 5(8); 860–77. ©2015 AACR.
This article is highlighted in the In This Issue feature, p. 783
Từ khóa
Tài liệu tham khảo
Chong, 2013, The quest to overcome resistance to EGFR-targeted therapies in cancer, Nat Med, 19, 1389, 10.1038/nm.3388
Shaw, 2013, ALK in lung cancer: past, present, and future, J Clin Oncol, 31, 1105, 10.1200/JCO.2012.44.5353
Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature, 503, 548, 10.1038/nature12796
Janne, 2013, Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study, Lancet Oncol, 14, 38, 10.1016/S1470-2045(12)70489-8
Berge, 2014, Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor, Semin Oncol, 41, 110, 10.1053/j.seminoncol.2013.12.006
Stinchcombe, 2014, MEK inhibition in non-small cell lung cancer, Lung Cancer, 86, 121, 10.1016/j.lungcan.2014.09.005
Singh, 2009, A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022
Ihle, 2012, Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome, J Natl Cancer Inst, 104, 228, 10.1093/jnci/djr523
Shepherd, 2013, Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy, J Clin Oncol, 31, 2173, 10.1200/JCO.2012.48.1390
Chen, 2012, A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response, Nature, 483, 613, 10.1038/nature10937
2014, Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma, Nature, 511, 543, 10.1038/nature13385
Brunet, 2004, Metagenes and molecular pattern discovery using matrix factorization, Proc Natl Acad Sci U S A, 101, 4164, 10.1073/pnas.0308531101
Gaujoux, 2010, A flexible R package for nonnegative matrix factorization, BMC Bioinformatics, 11, 367, 10.1186/1471-2105-11-367
Dabney, 2006, ClaNC: point-and-click software for classifying microarrays to nearest centroids, Bioinformatics, 22, 122, 10.1093/bioinformatics/bti756
Chitale, 2009, An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors, Oncogene, 28, 2773, 10.1038/onc.2009.135
Papadimitrakopoulou, 2013, BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC), ASCO Meeting Abstracts, 31, TPS8118
Imielinski, 2012, Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing, Cell, 150, 1107, 10.1016/j.cell.2012.08.029
Ding, 2008, Somatic mutations affect key pathways in lung adenocarcinoma, Nature, 455, 1069, 10.1038/nature07423
Tang, 2013, A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients, Clin Cancer Res, 19, 1577, 10.1158/1078-0432.CCR-12-2321
Mermel, 2011, GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome Biol, 12, R41, 10.1186/gb-2011-12-4-r41
Carter, 2012, Absolute quantification of somatic DNA alterations in human cancer, Nat Biotechnol, 30, 413, 10.1038/nbt.2203
de Bruin, 2014, Spatial and temporal diversity in genomic instability processes defines lung cancer evolution, Science, 346, 251, 10.1126/science.1253462
Zhang, 2014, Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing, Science, 346, 256, 10.1126/science.1256930
Schuster, 2014, Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis, Mol Cancer Res, 12, 912, 10.1158/1541-7786.MCR-13-0620-T
Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci U S A, 102, 15545, 10.1073/pnas.0506580102
Snyder, 2013, Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma, Mol Cell, 50, 185, 10.1016/j.molcel.2013.02.018
Maeda, 2012, Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung, J Clin Invest, 122, 4388, 10.1172/JCI64048
Liu, 2010, MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors, J Clin Invest, 120, 1298, 10.1172/JCI39566
Georges, 2008, Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215, Cancer Res, 68, 10105, 10.1158/0008-5472.CAN-08-1846
Eades, 2011, miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells, J Biol Chem, 286, 40725, 10.1074/jbc.M111.275495
Faubert, 2014, Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1alpha, Proc Natl Acad Sci U S A, 111, 2554, 10.1073/pnas.1312570111
Nosho, 2010, Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review, J Pathol, 222, 350, 10.1002/path.2774
Garnett, 2012, Systematic identification of genomic markers of drug sensitivity in cancer cells, Nature, 483, 570, 10.1038/nature11005
Tsai, 2015, The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss, Oncogene, 34, 1641, 10.1038/onc.2014.118
Carretero, 2010, Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors, Cancer Cell, 17, 547, 10.1016/j.ccr.2010.04.026
Liu, 2013, Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer, Cancer Discov, 3, 870, 10.1158/2159-8290.CD-13-0015
Marcu, 2002, Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha, Mol Cell Biol, 22, 8506, 10.1128/MCB.22.24.8506-8513.2002
Siegel, 2012, NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones, Biochem Pharmacol, 83, 1033, 10.1016/j.bcp.2011.12.017
Ji, 2007, LKB1 modulates lung cancer differentiation and metastasis, Nature, 448, 807, 10.1038/nature06030
Shackelford, 2013, LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin, Cancer Cell, 23, 143, 10.1016/j.ccr.2012.12.008
Jeon, 2012, AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress, Nature, 485, 661, 10.1038/nature11066
Alexander, 2010, ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS, Proc Natl Acad Sci U S A, 107, 4153, 10.1073/pnas.0913860107
Hart, 2012, ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth, J Clin Invest, 122, 4621, 10.1172/JCI62973
Kim, 2013, Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer, Cell, 155, 552, 10.1016/j.cell.2013.09.041
Quezada, 2011, Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication, Immunol Rev, 241, 104, 10.1111/j.1600-065X.2011.01007.x
Chen, 2014, Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression, Nat Commun, 5, 5241, 10.1038/ncomms6241
Rekhtman, 2013, KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma, Mod Pathol, 26, 1307, 10.1038/modpathol.2013.74
Nakada, 2013, The LKB1 tumor suppressor as a biomarker in mouse and human tissues, PLoS One, 8, e73449, 10.1371/journal.pone.0073449
Kaufman, 2014, LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT, J Thorac Oncol, 9, 794, 10.1097/JTO.0000000000000173
Zhu, 2010, Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer, J Clin Oncol, 28, 4417, 10.1200/JCO.2009.26.4325
Choi, 2009, Genetic diagnosis by whole exome capture and massively parallel DNA sequencing, Proc Natl Acad Sci U S A, 106, 19096, 10.1073/pnas.0910672106
Zhao, 2013, Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma, Proc Natl Acad Sci U S A, 110, 2916, 10.1073/pnas.1222577110
Choi, 2011, K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension, Science, 331, 768, 10.1126/science.1198785
Hodis, 2012, A landscape of driver mutations in melanoma, Cell, 150, 251, 10.1016/j.cell.2012.06.024
Frampton, 2013, Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol, 31, 1023, 10.1038/nbt.2696
Byers, 2013, An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, Clin Cancer Res, 19, 279, 10.1158/1078-0432.CCR-12-1558